Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs

International Journal of Antimicrobial Agents

Volumn 26, Issue 2, 2005, Pages 152-158

  Lenaerts, Anne J ^a   Johnson, Christine M ^a   Marrieta, Karen S ^a   Gruppo, Veronica ^a   Orme, Ian M ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Chemotherapy; Latency; Toxicity; Tuberculosis

Indexed keywords

EDETIC ACID; ISONIAZID; LIVER ENZYME; POLYMYXIN B NONAPEPTIDE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM CULTURE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CELL CULTURE; CONCENTRATION (PARAMETERS); DRUG DOSE REGIMEN; ENVIRONMENTAL FACTOR; ENZYME BLOOD LEVEL; FEMALE; IN VITRO STUDY; LIVER INJURY; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SERUM; TURBIDIMETRY;

ALANINE TRANSAMINASE; ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; LIVER; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 22544470588     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.04.011     Document Type: Article

References (28)

1. American Thoracic Society Targeted tuberculin testing and treatment of latent tuberculosis infection Am J Respir Crit Care Med 161 2000 S221 S247
2. Centers for Disease Control and Prevention Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001 MMWR Morb Mortal Wkly Rep 50 2001 733 735
3. Centers for Disease Control and Prevention Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection - New York and Georgia, 2000 MMWR Morb Mortal Wkly Rep 50 2001 289 291
4. Centers for Disease Control and Prevention Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003 MMWR Morb Mortal Wkly Rep 52 2003 735 739
5. P.D. Davies, and W.W. Yew Recent developments in the treatment of tuberculosis Expert Opin Investig Drugs 12 2003 1297 1312
6. F. Ballet Hepatotoxicity in drug development: detection, significance and solutions J Hepatol 26 1997 26 36
7. G.S. Smith, R.L. Hall, and R.M. Walker W.M. Haschek C.G. Rousseaux M.A. Wallig Handbook of toxicologic pathology vol. 2 2002 Academic Press San Diego, CA [Chapter 31]
8. B.P. Kelly, S.K. Furney, M.T. Jessen, and I.M. Orme Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis Antimicrob Agents Chemother 40 1996 2809 2812
9. A.J. Lenaerts, V. Gruppo, J.V. Brooks, and I.M. Orme Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice Antimicrob Agents Chemother 47 2003 783 785
10. WHO-ART Adverse Drug Reaction Terminology. WAADR. Geneva, Austria: WHO Collaborating Center for International Drug Monitoring; 1979.
11. M.H. Cynamon, S.P. Klemens, C.A. Sharpe, and S. Chase Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model Antimicrob Agents Chemother 43 1999 1189 1191
12. B. Ji, N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis Antimicrob Agents Chemother 42 1998 2066 2069
13. B. Ji, N. Lounis, C. Truffot-Pernot, and J. Grosset In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis Antimicrob Agents Chemother 39 1995 1341 1344
14. S.P. Klemens, M.A. Grossi, and M.H. Cynamon Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model Antimicrob Agents Chemother 38 1994 2245 2248
15. S.P. Klemens, C.A. Sharpe, M.C. Rogge, and M.H. Cynamon Activity of levofloxacin in a murine model of tuberculosis Antimicrob Agents Chemother 38 1994 1476 1479
16. G. Canetti, F. Grumbach, and J. Grosset Long-term, two-stage chemotherapy of advanced experimental murine tuberculosis with intermittent regimens during the second stage Tubercle 44 1963 236 240
17. J.M. Dickinson, and D.A. Mitchison Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis Tubercle 49 1968 351 365
18. J.M. Dickinson, and D.A. Mitchison Suitability of rifampicin for intermittent administration in the treatment of tuberculosis Tubercle 51 1970 82 94
19. J. Grosset The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy Tubercle 59 1978 287 297
20. M.J.A. Lenaerts, S.E. Chase, A.J. Chmielewski, and M.H. Cynamon Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice Antimicrob Agents Chemother 43 1999 2356 2360
21. A. Medinger Death associated with rifampin and pyrazinamide 2-month treatment of latent Mycobacterium tuberculosis Chest 121 2002 1710 1712
22. L. McNeill, M. Allen, C. Estrada, and P. Cook Pyrazinamide and rifampin vs. isoniazid for the treatment of latent tuberculosis Chest 123 2003 102 106
23. D. Yee, C. Valiquette, M. Pelletier, I. Parisien, I. Rocher, and D. Menzies Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis Am J Respir Crit Care Med 167 2003 1472 1477
24. D.I. Horn, D. Hewlett, C. Alfalla, S. Peterson, and S.M. Opal Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis N Engl J Med 330 1994 1241
25. H.X. Lou, M.A. Shullo, and T.P. McKaveney Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population Pharmacotherapy 22 2002 701 704
26. T. Papastavros, L.R. Dolovich, A. Holbrook, L. Whitehead, and M. Loeb Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis CMAJ 167 2002 131 136
27. J.P. Stevens, and T.M. Daniel Chemoprophylaxis of multidrug-resistant tuberculosis infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis Chest 108 1995 712 717
28. R. Rizdon, J. Meador, R. Maxwell, K. Higgins, P. Weismuller, and I.M. Onorato Asymptomatic hepatitis in persons who received alternative preventative therapy with pyrazinamide and ofloxacin Clin Infect Dis 24 1997 1265 1267